

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

Drug	indacaterol maleate
Brand Name	Onbrez® Breezehaler®
Dosage Form(s)	75 mcg
Manufacturer	Novartis Pharmaceuticals Canada Inc.
Submission Review	New Submission
Use Reviewed	Indacaterol is indicated for long-term, maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD)
Common Drug Review (CDR)	Yes: CDR recommended to List with criteria http://www.cadth.ca/media/cdr/complete/cdr_complete_Onbrez_Aug-20-12_e.pdf
Drug Benefit Council (DBC)	DBC met on February 18, 2013. DBC considered the following: final review completed by the Common Drug Review (CDR) on August 16, 2012, which included clinical and pharmaco-economic evidence review material and the recommendation from the Canadian Drug Expert Committee (CDEC). The DBC also considered Patient Input Questionnaire responses from 6 patients and 1 patient group, Clinical Practice Reviews from 1 specialist and 1 general physician, manufacturer comments, as well as a Budget Impact Assessment.
Drug Coverage Decision	indacaterol maleate (Onbrez® Breezehaler®) : Limited Coverage Benefit with criteria http://www.health.gov.bc.ca/pharmacare/sa/criteria/restricted/indacterolmaleate.html
Date	May 30, 2013
Reason(s)	Drug coverage decision is consistent with the DBC recommendation. <ul style="list-style-type: none"> • The drug demonstrated some advantage over placebo with respect to efficacy.. • The drug was similar to other treatments for COPD with respect to efficacy and safety. • Based on economic considerations and the product price, the drug was cost effective.
Other Information	None

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council](#) gives advice to the Ministry. The Council looks at:

- advice from a national group called the Common Drug Review
- whether the drug is safe and effective
- whether it is a good value for the people of B.C. and the drugs cost
- the ethics of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a decision based on many factors, including:

- advice from the Council
- drugs used to treat similar medical conditions that B.C. PharmaCare already covers
- the overall cost of covering the drug

For more information about the B.C. Drug Review Process, please visit
<http://www.health.gov.bc.ca/pharmacare/outgoing/drugrevproc2.pdf>.

To find out more about the Pharmaceutical Services Division and the PharmaCare program, visit
www.health.gov.bc.ca/pharmacare.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.